STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK Medicines and Healthcare products Regulatory Agency (MHRA) officially approved/authorised orforglipron (Foundayo).
August 24, 2026: Commercial Launch — Eli Lilly officially launched the drug in the UK, making it available to patients via private prescriptions.
The Real GLP-1 War in India: When the Molecule Becomes a Commodity, What Becomes the Moat?
The GLP-1 revolution has entered a new phase: competition now shifts from the molecule to everything around it. Eli Lilly's Foundayo (orforglipron) launched in the UK, making Britain the first European market for Lilly's once-daily oral GLP-1. Unlike oral semaglutide, orforglipron is a non-peptide small molecule: no food/water restrictions, no sterile injection devices, no complex fill-finish, and no refrigeration. For India, where Novo Nordisk's core semaglutide patent expired on March 20, 2026, the strategic stakes are clear: competitors must now win on distribution, adherence, trust, and ecosystem support, not just on the molecule. As the molecule becomes a commodity, competitive advantage shifts to everything surrounding it.
Free Membership Required
You must be a Free member to access this content.
